The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.
TScan Therapeutics, a US-based T-cell immunotherapy developer backed by internet and technology group Alphabet and pharmaceutical firms Astellas, Novartis and WuXi AppTec, has filed for an initial public offering (IPO).
The company has set a placeholder figure of $100m and intends to float on the Nasdaq Global Market. Morgan Stanley, Jefferies, Cowen and Barclays Capital are underwriters for the IPO.
Founded in 2018, TScan is developing T-cell therapies to target haematological and solid tumours. Its TargetScan tool analyses cancer…
